Micafungin: Difference between revisions
Jump to navigation
Jump to search
Ahmed Zaghw (talk | contribs) No edit summary |
Ahmed Zaghw (talk | contribs) No edit summary |
||
| Line 10: | Line 10: | ||
Antifungal drug | Antifungal drug | ||
==US Brand Names== | ==US Brand Names== | ||
Mycamine<sup>®</sup> | '''Mycamine<sup>®</sup>''' | ||
==FDA Package Insert== | ==FDA Package Insert== | ||
Revision as of 06:04, 9 January 2014
For patient information, click here.
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]
Overview
Category
Antifungal drug
US Brand Names
Mycamine®
FDA Package Insert
Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings and Precautions | Adverse Reactions | Drug Interactions | Overdosage | Clinical Studies | Dosage and Administration | How Supplied | Labels and Packages
Mechanism of Action
Micafungin inhibits the synthesis of 1, 3-beta-D-glucan, an essential component of fungal cell walls.